

Updated: 07/2023 DMMA Approved: 07/2023

Request for Prior Authorization for Livmarli (maralixibat) Website Form – www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158

All requests for Livmarli (maralixibat) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Livmarli (maralixibat) Prior Authorization Criteria:

Coverage may be provided with a diagnosis of **cholestatic pruritis** caused by **Alagille syndrome** (ALGS) and the following criteria is met:

- Member must be > 3 months old
- Must be prescribed by or in consultation with a hepatologist or gastroenterologist
- Must have diagnosis confirmed by genetic testing
- Must provide documentation showing the member has tried and failed or had an intolerance or contraindication to BOTH of the following:
 - o Bile acid sequestrants (i.e. cholestyramine, colesevelam, or colestipol)
 - o Ursodiol
- Must provide baseline documentation of BOTH of the following:
 - Liver function tests
 - o Fat-soluble vitamin levels
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 3 months
- Reauthorization criteria
 - o Must submit LFTs within past 3 months
 - o Must submit fat-soluble vitamin levels within past 3 months
 - Documentation of improvement of pruritus
 - o Must provide dosing plan for continued use if no documented clinical benefit
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.



Updated: 07/2023 DMMA Approved: 07/2023

LIVMARLI (MARALIXIBAT) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. FAX: (855) 476-4158

If needed, you may call to speak to a Pharmacy Services Representative. PHONE: (844) 325-6251 Mon – Fri 8 am to 7 pm PROVIDER INFORMATION Requesting Provider: NPI: Provider Specialty: Office Contact: Office Address: Office Phone: Office Fax: MEMBER INFORMATION DOB: Member Name: Member ID: Member weight: Height: REQUESTED DRUG INFORMATION Medication: Strength: Ouantity: Refills: Directions: Is the member currently receiving requested medication? \(\subseteq \text{Yes} \) □ No Date Medication Initiated: Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the ☐ Yes ☐ No patient? **Billing Information** This medication will be billed: \[\] at a pharmacy **OR** \[\] medically, JCODE: Place of Service: Hospital Provider's office Member's home Other Place of Service Information NPI: Name: Phone: Address: **MEDICAL HISTORY (Complete for ALL requests)** Diagnosis: ICD Code: Has diagnosis been confirmed by genetic testing?

Yes No Is pruritis present? Yes No Have baseline fat-soluble vitamin levels been checked? Yes No What has been tried? Check all that apply and provide the information below. Bile acid sequestrant (e.g. cholestyramine, colesevelam, colestipol) Ursodiol **CURRENT or PREVIOUS THERAPY Medication Name** Strength/ Frequency **Dates of Therapy Status (Discontinued & Why/Current)** REAUTHORIZATION Have LFT's been checked within the past 3 months? ☐ Yes ☐ No Have fat-soluble vitamin levels been checked within the past 3 months? ☐ Yes ☐ No SUPPORTING INFORMATION or CLINICAL RATIONALE **Prescribing Provider Signature** Date